FRENCH pharmaceutical giant Sanofi today forecast slower earnings growth for 2023 after profits jumped last year on the back of popular eczema and asthma drug Dupixent.
The company’s net profit rose by 8% to €6.7 billion (RM31.15 billion) last year.